ImmuneRegen BioSciences, Inc.
4021 N. 75th At., Suite 201
Scottsdale
Arizona
85251
United States
Tel: 480-922-3926 or 866-922-3926
Fax: 480-222-3295
Website: http://www.immuneregen.com/
Email: nfo@immuneregen.com
99 articles about ImmuneRegen BioSciences, Inc.
-
ImmuneRegen BioSciences, Inc. Reports Positive Results in Cancer Vaccine Studies in Radboud University Nijmegen Medical Centre Collaboration
10/28/2010
-
ImmuneRegen BioSciences, Inc. Reports Scancell Collaboration Yielding Positive Results in Cancer Vaccine Studies of Homspera(R)
9/8/2010
-
Scancell Release: Collaboration With ImmuneRegen BioSciences, Inc. Yields Positive Results in Cancer Vaccine Studies
9/7/2010
-
ImmuneRegen BioSciences, Inc. Invited to Submit Full Proposal to Biomedical Advanced Research and Development Authority (BARDA) for Homspera(R) as a Potential Medical Countermeasure for Injury Associated With Radiation Exposure
8/31/2010
-
University of Rochester Medical Center Receives $15 Million in Government Funding to Research ImmuneRegen BioSciences, Inc.'s Homspera(R)
8/25/2010
-
ImmuneRegen BioSciences, Inc. Completes Successful Reduction of Debt
8/4/2010
-
Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences, Inc.(R)
6/4/2010
-
ImmuneRegen BioSciences, Inc. Announces Collaboration With the Department of Tumor Immunology of the Radboud University Nijmegen Medical Centre, the Netherlands
4/27/2010
-
NeoStem, Inc. and ImmuneRegen BioSciences, Inc. to Collaborate on Stem Cells
4/22/2010
-
ImmuneRegen BioSciences, Inc. Initiates Strategic Collaboration With MPI Research to Accelerate Clinical Development of Lead Indications
4/21/2010
-
ImmuneRegen BioSciences, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
4/19/2010
-
ImmuneRegen BioSciences, Inc. Submits Homspera(R) for FDA Orphan Drug Product Designation for the Treatment of Idiopathic Pulmonary Fibrosis
3/4/2010
-
Fred Hutchinson Cancer Research Center Initiates Studies on ImmuneRegen BioSciences, Inc.'s Cancer Therapy Candidate
2/10/2010
-
National Cancer Institute Initiates Studies on ImmuneRegen BioSciences, Inc.' Vaccine Adjuvant Candidate
1/27/2010
-
ImmuneRegen BioSciences, Inc. Reports Additional Positive Results From Study of Homspera(R) in Treating Highly Pathogenic Influenza
1/5/2010
-
ImmuneRegen BioSciences, Inc. Summarizes Previous 9 Months of Advances as Homspera(R) Development Continues
12/28/2009
-
ImmuneRegen BioSciences, Inc. Reports Efficacy of a New Adjuvant of a Preventive Cancer Vaccine
12/21/2009
-
ImmuneRegen BioSciences, Inc. Drug Candidate Homspera Confirms Efficacy as Cancer Vaccine Adjuvant
12/14/2009
-
ImmuneRegen BioSciences, Inc. Reports Positive Results of Homspera(R) in Treating Highly Pathogenic Influenza
11/10/2009
-
ImmuneRegen BioSciences, Inc. to Further Homspera(R) Research in Study Funded by U.S. Government
10/22/2009